ORKA-001-114: Moderate-to-Severe Plaque Psoriasis

Recruiting
18 years - 99 years
All
Phase N/A
1 Location

Brief description of study

This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of ORKA-001, a biologic targeting IL-23, in adults with moderate-to-severe plaque psoriasis. Participants will undergo screening labs, questionnaires, physical exams, and receive subcutaneous study drug or placebo with regular safety and efficacy assessments.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Plaque Psoriasis
  • Age: 18 years - 99 years
  • Gender: All

Key Eligibility Criteria:

  • Age 18 or older
  • Diagnosis of stable chronic plaque psoriasis (± psoriatic arthritis) for ≥6 months
  • ≥10% body surface area affected
  • Candidate for systemic therapy or phototherapy
  • No prior use of Skyrizi, Tremfya, or Ilumya
  • Other biologic therapy washout: minimum of 5 half-lives
  • Oral anti-psoriatic medications: washout of >4 weeks
  • Topical anti-psoriatic medications: washout of >2 weeks

Updated on 02 Apr 2026. Study ID: 25-1966

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center